These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32624198)

  • 1. Select Stabilization of a Tumor-Suppressive PP2A Heterotrimer.
    Shah VM; English IA; Sears RC
    Trends Pharmacol Sci; 2020 Sep; 41(9):595-597. PubMed ID: 32624198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective PP2A Enhancement through Biased Heterotrimer Stabilization.
    Leonard D; Huang W; Izadmehr S; O'Connor CM; Wiredja DD; Wang Z; Zaware N; Chen Y; Schlatzer DM; Kiselar J; Vasireddi N; Schüchner S; Perl AL; Galsky MD; Xu W; Brautigan DL; Ogris E; Taylor DJ; Narla G
    Cell; 2020 Apr; 181(3):688-701.e16. PubMed ID: 32315618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biased holoenzyme assembly of protein phosphatase 2A (PP2A): From cancer to small molecules.
    Haanen TJ; O'Connor CM; Narla G
    J Biol Chem; 2022 Dec; 298(12):102656. PubMed ID: 36328247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein phosphatase 2A: a target for anticancer therapy.
    Perrotti D; Neviani P
    Lancet Oncol; 2013 May; 14(6):e229-38. PubMed ID: 23639323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth.
    Umesalma S; Kaemmer CA; Kohlmeyer JL; Letney B; Schab AM; Reilly JA; Sheehy RM; Hagen J; Tiwari N; Zhan F; Leidinger MR; O'Dorisio TM; Dillon J; Merrill RA; Meyerholz DK; Perl AL; Brown BJ; Braun TA; Scott AT; Ginader T; Taghiyev AF; Zamba GK; Howe JR; Strack S; Bellizzi AM; Narla G; Darbro BW; Quelle FW; Quelle DE
    J Clin Invest; 2019 Mar; 129(4):1641-1653. PubMed ID: 30721156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Druggable cancer phosphatases.
    Vainonen JP; Momeny M; Westermarck J
    Sci Transl Med; 2021 Apr; 13(588):. PubMed ID: 33827975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.
    Farrington CC; Yuan E; Mazhar S; Izadmehr S; Hurst L; Allen-Petersen BL; Janghorban M; Chung E; Wolczanski G; Galsky M; Sears R; Sangodkar J; Narla G
    J Biol Chem; 2020 Jan; 295(3):757-770. PubMed ID: 31822503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein Phosphatase 2A: a Double-Faced Phosphatase of Cellular System and Its Role in Neurodegenerative Disorders.
    Nematullah M; Hoda MN; Khan F
    Mol Neurobiol; 2018 Feb; 55(2):1750-1761. PubMed ID: 28224476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PP2A: unveiling a reluctant tumor suppressor.
    Mumby M
    Cell; 2007 Jul; 130(1):21-4. PubMed ID: 17632053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PP2A Phosphatase as an Emerging Viral Host Factor.
    Barski MS; Minnell JJ; Maertens GN
    Front Cell Infect Microbiol; 2021; 11():725615. PubMed ID: 34422684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles and regulation of protein phosphatase 2A (PP2A) in the heart.
    Lubbers ER; Mohler PJ
    J Mol Cell Cardiol; 2016 Dec; 101():127-133. PubMed ID: 27832939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restricted protein phosphatase 2A targeting by Merkel cell polyomavirus small T antigen.
    Kwun HJ; Shuda M; Camacho CJ; Gamper AM; Thant M; Chang Y; Moore PS
    J Virol; 2015 Apr; 89(8):4191-200. PubMed ID: 25631078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of AMP Kinase by the Protein Phosphatase 2A Heterotrimer, PP2APpp2r2d.
    Joseph BK; Liu HY; Francisco J; Pandya D; Donigan M; Gallo-Ebert C; Giordano C; Bata A; Nickels JT
    J Biol Chem; 2015 Apr; 290(17):10588-98. PubMed ID: 25694423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of protein phosphatase 2A regulatory subunit B56δ promotes spontaneous tumorigenesis in vivo.
    Lambrecht C; Libbrecht L; Sagaert X; Pauwels P; Hoorne Y; Crowther J; Louis JV; Sents W; Sablina A; Janssens V
    Oncogene; 2018 Jan; 37(4):544-552. PubMed ID: 28967903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PP2A Inactivation Mediated by
    Sents W; Meeusen B; Kalev P; Radaelli E; Sagaert X; Miermans E; Haesen D; Lambrecht C; Dewerchin M; Carmeliet P; Westermarck J; Sablina A; Janssens V
    Cancer Res; 2017 Dec; 77(24):6825-6837. PubMed ID: 29046336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A SMAP in the face for cancer.
    Shenolikar S
    J Clin Invest; 2017 Jun; 127(6):2048-2050. PubMed ID: 28504652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents.
    Brautigan DL; Farrington C; Narla G
    Clin Sci (Lond); 2021 Jul; 135(13):1545-1556. PubMed ID: 34192314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapies don't work for a reason; the neglected tumor suppressor phosphatase PP2A strikes back.
    Westermarck J
    FEBS J; 2018 Nov; 285(22):4139-4145. PubMed ID: 30055114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer.
    Switzer CH; Glynn SA; Ridnour LA; Cheng RY; Vitek MP; Ambs S; Wink DA
    Trends Pharmacol Sci; 2011 Nov; 32(11):644-51. PubMed ID: 21893353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.